To identify additional MSI2 direct targets that promote resistance to PRMT5 inhibition in B-cell lymphoma, we overlapped: 1) differentially expressed genes in Z-138 cells treated with Ro, GSK-591 and the combination (DeSeq data), 2) the Ro-specific MSI2 targets (HyperTRIBE) and 3) genes that confer resistance to PRMT5 inhibition (genome-wide CRISPR screen). This evidence concerns the gene MSI2 and B-cell non-Hodgkin lymphoma.